Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • The Discussion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

New findings targeting GPR56 could pave the way for the development of new treatments of depressive disorders

Staff Writer
Staff Writer 2 years ago
Updated 2020/04/08 at 12:51 PM
Share
SHARE

On a global scale, more than 260 million people of different age groups suffer from depression, according to the World Health Organization. To alleviate symptoms, clinicians generally administer antidepressants, however, many don’t respond well to the first antidepressant they try.

In a recent study appearing in Nature Communications, a Canadian research group at McGill University, in collaboration with the Douglas Mental Health University Institute, probed G protein-coupled receptor 56 (GPR56), a protein encoded by the ADGRG1 gene.

Based on their study, GRP56 is likely implicated in the neurobiological process of depression and could therefore expand our comprehension of antidepressant efficacy and pave the way for new treatments.

As published in the findings, the group of researchers were led to those conclusions by probing 424 patients undergoing treatment for a depressive disorder with an serotonin-norepinephrine inhibitor (SNRI) antidepressant. Blood tests were taken of the patients, identifying for any changes in the activity of genes in the blood during their course of drug therapy.

“In three cohorts of individuals with depression and treated with serotonin-norepinephrine reuptake inhibitor we show that responders, but not non-responders, display an increase of GPR56 mRNA in the blood,” the study’s co-authors explained

“In mice, we show that chronic stress-induced Gpr56 downregulation in the blood and prefrontal cortex (PFC), which is accompanied by depression-like behavior, and can be reversed by antidepressant treatment.”

“Gpr56 knockdown in mouse PFC is associated with depressive-like behaviors, executive dysfunction and poor response to antidepressant treatment.”

In the results, drastic alterations in the levels of GRP56 was evident only among patients who saw some benefit to antidepressants. As a result, researcher suggest GRP56 might serve as a biomarker for antidepressant efficacy.

“Our results provide a greater understanding of the pathophysiology of depression, and suggest a drug target for the treatment of major depressive disorder (MDD).”

Photo: depositphotos.com

You Might Also Like

MIT study shows how microglia can contribute to Alzheimer’s disease

New paper refutes theory that the human brain shrank 3,000 years ago

New study finds that people with autism are more skilled at reading emotions in cartoons

New report explores the link between dementia and air pollution

How herpes simplex virus may help trigger the onset of Alzheimer’s disease

TAGGED: GPR56, antidepressants, depression
Staff Writer April 8, 2020
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Older Americans more likely than younger adults to view COVID-19 pandemic as a major threat to their health
Next Article Researchers probe the association between mild behavioral impairment and early Alzheimer’s disease pathology

Recommended

Clinical

MIT study shows how microglia can contribute to Alzheimer’s disease

1 Min Read
Clinical

New paper refutes theory that the human brain shrank 3,000 years ago

1 Min Read
Clinical

New study finds that people with autism are more skilled at reading emotions in cartoons

1 Min Read
Clinical

New report explores the link between dementia and air pollution

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?